Impact of age and sex on survival outcomes in patients aged 1-45 years with acute lymphoblastic leukemia treated according to the stratification used in the NOPHO ALL2008 trial.
Tuomas Lahteenmaki Taalas, Trausti Oskarsson, Mats Heyman, Bendik Lund, Kristi Lepik, Goda Vaitkevičiene, Olafur Gisli Jonsson, Julia Eriksson, Nina Toft, Laimonas Griškevičius, Helene Hallbook, Katrin Palk, Ulla Wartiovaara-Kautto, Petter Quist-Paulsen, Ulrika Noren-Nystrom, Kim Vettenranta, Jonas Abrahamsson, Kjeld Schmiegelow, Paivi M Lahteenmaki
{"title":"Impact of age and sex on survival outcomes in patients aged 1-45 years with acute lymphoblastic leukemia treated according to the stratification used in the NOPHO ALL2008 trial.","authors":"Tuomas Lahteenmaki Taalas, Trausti Oskarsson, Mats Heyman, Bendik Lund, Kristi Lepik, Goda Vaitkevičiene, Olafur Gisli Jonsson, Julia Eriksson, Nina Toft, Laimonas Griškevičius, Helene Hallbook, Katrin Palk, Ulla Wartiovaara-Kautto, Petter Quist-Paulsen, Ulrika Noren-Nystrom, Kim Vettenranta, Jonas Abrahamsson, Kjeld Schmiegelow, Paivi M Lahteenmaki","doi":"10.3324/haematol.2024.286043","DOIUrl":null,"url":null,"abstract":"<p><p>Age and sex have historically been associated with differences in acute lymphoblastic leukemia (ALL) survival. In the NOPHO ALL2008 trial, patients aged 1-45 years with BCR::ABL1-negative B-precursor and Tcell ALL were included, but neither sex nor age was integrated into risk group allocation. Among 1,771 trial patients stratified into protocol-appropriate risk groups, we estimated the impact of age and sex on survival (even after relapse) and toxicities prospectively registered at three-month intervals. In multivariate Cox regression analysis adjusted by sex, age group, and risk group, age but not sex was an independent risk factor for reduced 5-year event-free survival (EFS), hazard ratio 1.57 (95%CI 1.15-2.14) for patients 10-17.9 years, and 2.70 (2.03-3.58) for patients 18-45 years, compared to patients.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":8.2000,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Haematologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3324/haematol.2024.286043","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Age and sex have historically been associated with differences in acute lymphoblastic leukemia (ALL) survival. In the NOPHO ALL2008 trial, patients aged 1-45 years with BCR::ABL1-negative B-precursor and Tcell ALL were included, but neither sex nor age was integrated into risk group allocation. Among 1,771 trial patients stratified into protocol-appropriate risk groups, we estimated the impact of age and sex on survival (even after relapse) and toxicities prospectively registered at three-month intervals. In multivariate Cox regression analysis adjusted by sex, age group, and risk group, age but not sex was an independent risk factor for reduced 5-year event-free survival (EFS), hazard ratio 1.57 (95%CI 1.15-2.14) for patients 10-17.9 years, and 2.70 (2.03-3.58) for patients 18-45 years, compared to patients.
期刊介绍：
Haematologica is a journal that publishes articles within the broad field of hematology. It reports on novel findings in basic, clinical, and translational research.
Scope:
The scope of the journal includes reporting novel research results that:
Have a significant impact on understanding normal hematology or the development of hematological diseases.
Are likely to bring important changes to the diagnosis or treatment of hematological diseases.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
